IDH2 and acute myeloid leukemia: Ivosidenib (AG-120) is an oral inhibitor of the IDH1 mutated enzyme, while enasidenib (AG-221) inhibits mutated IDH2; both are approved for the treatment of acute myeloid leukaemia (AML).